Navigation Links
Medivation Announces Organizational Changes to Support Anticipated Growth and Future Commercialization
Date:12/17/2009

imebon.

About Medivation

Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. In September 2008, Medivation announced a global agreement with Pfizer, Inc to develop and commercialize dimebon (latrepirdine) for the treatment of Alzheimer's and Huntington diseases. With Pfizer, Medivation is conducting a broad dimebon clinical development program that includes several Phase 3 trials assessing the efficacy and safety of dimebon taken alone or in combination with other Alzheimer's medications in patients with mild, moderate and severe Alzheimer's disease. The companies are also conducting a Phase 3 trial of dimebon in Huntington disease. In October 2009, Medivation entered a global agreement with Astellas Pharma Inc. to develop and commercialize MDV3100 for prostate cancer. The first Phase 3 clinical trial in the MDV3100 development program, known as the AFFIRM trial, is under way in patients with castration-resistant prostate cancer who have previously been treated with docetaxel-based chemotherapy. For more information, please visit us at http://www.medivation.com.

This press release contains forward-looking statements, including statements regarding the commercialization of dimebon and Medivation's transition from a development stage company to a commercial organization, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements involve risks and uncertainties
'/>"/>

SOURCE Medivation, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Medivation Reports Third Quarter 2009 Financial Results and Provides Corporate Update
2. Astellas and Medivation Enter Into Worldwide Agreement to Co-Develop and Co-Commercialize MDV3100 for the Treatment of Prostate Cancer
3. Medivation Announces Initiation of Phase 3 Clinical Trial of MDV3100 in Advanced Prostate Cancer
4. Medivation Announces Positive New Efficacy Data From Phase 1-2 Trial of MDV3100 in Advanced Prostate Cancer Patients
5. Pfizer and Medivation Initiate Phase 3 Trial of Dimebon Added to Donepezil in Patients with Alzheimers Disease
6. Medivation Completes Enrollment of Phase 1-2 Trial of MDV3100 in Castration-Resistant Prostate Cancer Patients
7. Medivation Presents Positive New Data on Dimebons Long-Term Efficacy and Novel Mechanism of Action at the International Conference on Alzheimers Disease
8. Medivation Announces Publication in The Lancet of Dimebon Pivotal Trial Results in Alzheimers Disease
9. Medivation Announces Positive Top-Line Results From Phase 2 Dimebon Study in Huntingtons Disease
10. Medivation to Host Conference Call at 5 p.m. EDT Monday to Discuss Top-Line Phase 2 Study Results in Huntingtons Disease
11. Medivation Initiates Second Pivotal Phase 3 Trial of Dimebon(TM) in Patients With Alzheimers Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)...   MedeAnalytics today unveils Revenue Integrity, ... visibility to a provider,s "mid-cycle" to optimize revenue ... Powered by the industry,s leading big data platform, ... between patient access and the business office where ... revenue capture, minimize audit risk and prepare providers ...
(Date:9/17/2014)... --  myMatrixx, a pharmacy and ancillary medical benefit manager for workers, ... has awarded myMatrixx with a "Best Places to Work ... row. Best Places to Work is ... Best Companies Group.  The competition, which involves months of ... insurance industry companies with at least 25 employees in ...
(Date:9/17/2014)... MADISON, Tenn. , Sept. 17, 2014 ... be; these infections are not only uncomfortable, they,re often ... best-laid social plans. pH-D Feminine Health Support ( http://ph-defense.com ... vaginal health. It is an all-natural, homeopathic product. ... the most common symptoms of vaginal infection. In many ...
Breaking Medicine Technology:MedeAnalytics Unveils New Revenue Integrity Solution to Support the Transition to Value-Based Healthcare 2MedeAnalytics Unveils New Revenue Integrity Solution to Support the Transition to Value-Based Healthcare 3myMatrixx Honored with "Best Places to Work in Insurance" Award 2New Product from Vireo Systems: pH-D Feminine Health Support 2
... FRANCISCO, Calif., Aug. 25, 2011 Rigel Pharmaceuticals, Inc. ... M. Gower, chairman and chief executive officer, and Ryan ... Rigel, will present at two separate investor conferences in ... Healthcare Conference 2011Date: Thursday, September 8th at 10:20 a.m. ...
... Nutrastar International Inc. (OTCBB: NUIN; "Nutrastar" or the "Company"), ... Chinese Medicine ("TCM") consumer products, today announced that its ... under which Nutrastar may repurchase up to US$5 million ... 12 months. Under the program, the ...
Cached Medicine Technology:Nutrastar Announces Adoption of Share Repurchase Program 2Nutrastar Announces Adoption of Share Repurchase Program 3
(Date:9/18/2014)... MD (PRWEB) September 18, 2014 A ... shaping system has been approved by the United States Food ... available for widespread purchase in the US, landmark dermatology center ... and only practices on the east coast to use this ... only practice in the Baltimore area to offer patients the ...
(Date:9/18/2014)... (PRWEB) September 18, 2014 Members ... online with participating network dentists at UnitedConcordia.com, thanks ... dental wellness company. , "Members can book an ... 'Schedule Now' button located on the Find a ... vice president of network operations at United Concordia. ...
(Date:9/18/2014)... 2014 MD Complete , the ... a prescription, announced today that SHAPE Magazine has named ... “Best Peel” in its annual Beauty Awards. The issue ... beauty products as tested by SHAPE’s expert team. , ... results. Among the thousands of beauty products launched every ...
(Date:9/18/2014)... 2014 One Week Kitchens will have their ... Fair beginning this Saturday. Their display will be inside the ... of the products and design services that are offered at ... for fair-goers to see. This display won ‘Most Beautiful Display’ ... year and really is something to see. , The ...
(Date:9/18/2014)... (PRWEB) September 18, 2014 Each year, ... of activities that coincide with National Health IT (NHIT) ... (IT/IS) professionals. To help Norman Regional show its gratitude, ... for hospitals , is contributing giveaway items to support ... a prize drawing and offering free lunches, Norman Regional ...
Breaking Medicine News(10 mins):Health News:New FDA-Approved UltraShape Body Contouring Procedure Comes to Maryland Laser Skin and Vein 2Health News:United Concordia Offers Real-time Online Scheduling for their Members, Through LocalMed 2Health News:United Concordia Offers Real-time Online Scheduling for their Members, Through LocalMed 3Health News:MD Complete Wins Shape Beauty Award for Best Peel 2Health News:One Week Kitchens Taking Display to Bloomsburg Fair 2Health News:Access Helps Norman Regional Hospital Celebrate Its Staff During National Health IT Week 2014 2
... Technologies, Inc. (Nasdaq: EFJI ) today announced its ... revenues decreased $11.5 million, or 34%, to $22.4 million for ... for the same period in 2008. This anticipated quarterly decline ... in revenues associated with the FCC re-banding effort. "While our ...
... May 6 NeoStem, Inc. (NYSE Amex: ... and long-term storage of adult stem cells for future ... proprietary stem cell technology of Vincent C. Giampapa, ... first licensed in February 2009.The newest adult stem cell ...
... Pharmaceuticals Corp., a developer and manufacturer of medical products that ... the first quarter of 2009. , For the quarter ended ... million, or $0.06 cents per share, on revenues of $4.1 ... or $0.12 cents per share, on revenues of $5.2 million ...
... EntreMed, Inc. (Nasdaq: ENMD ), a ... cancer and inflammatory diseases, today reported financial results for ... http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO ) , The Company ... approximately ($3.5 million), or ($0.04) per share, compared with ...
... cancers at Women,s Dermatologic Society outreach at Family Circle ... safety and skin health, South Carolina physicians representing the ... cancer screenings and education for fans enjoying the Family ... day of outreach, local dermatologists referred 38% of the ...
... May 6 Micromet, Inc. (Nasdaq: MITI ... the treatment of cancer, inflammation and autoimmune diseases, today ... March 31, 2009.In the first quarter of 2009, Micromet ... progress in the clinic and in corporate development. ...
Cached Medicine News:Health News:EF Johnson Technologies, Inc. Announces First Quarter 2009 Financial Results 2Health News:EF Johnson Technologies, Inc. Announces First Quarter 2009 Financial Results 3Health News:EF Johnson Technologies, Inc. Announces First Quarter 2009 Financial Results 4Health News:EF Johnson Technologies, Inc. Announces First Quarter 2009 Financial Results 5Health News:EF Johnson Technologies, Inc. Announces First Quarter 2009 Financial Results 6Health News:NeoStem Files Patent Application for Cosmetic Stem Cell Face Lift Technology and Expands Stem Cell Collection Network into New Jersey 2Health News:NeoStem Files Patent Application for Cosmetic Stem Cell Face Lift Technology and Expands Stem Cell Collection Network into New Jersey 3Health News:NUCRYST announces 2009 first quarter financial results 2Health News:NUCRYST announces 2009 first quarter financial results 3Health News:NUCRYST announces 2009 first quarter financial results 4Health News:NUCRYST announces 2009 first quarter financial results 5Health News:NUCRYST announces 2009 first quarter financial results 6Health News:NUCRYST announces 2009 first quarter financial results 7Health News:EntreMed Reports First Quarter 2009 Financial Results 2Health News:EntreMed Reports First Quarter 2009 Financial Results 3Health News:South Carolina Dermatologists Win Tennis Fans' Attention With Free Skin Cancer Checks and Sun Safety Tips 2Health News:South Carolina Dermatologists Win Tennis Fans' Attention With Free Skin Cancer Checks and Sun Safety Tips 3Health News:Micromet, Inc. Reports First Quarter 2009 Financial Results 2Health News:Micromet, Inc. Reports First Quarter 2009 Financial Results 3Health News:Micromet, Inc. Reports First Quarter 2009 Financial Results 4Health News:Micromet, Inc. Reports First Quarter 2009 Financial Results 5Health News:Micromet, Inc. Reports First Quarter 2009 Financial Results 6Health News:Micromet, Inc. Reports First Quarter 2009 Financial Results 7Health News:Micromet, Inc. Reports First Quarter 2009 Financial Results 8Health News:Micromet, Inc. Reports First Quarter 2009 Financial Results 9
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: